220298-96-4

Basic information

• Product Name: tert-Butyl N-[4-(aminomethyl)phenyl]carbamate
• Synonyms: 2-(4-CHLOROPHENOXY)MALONDIALDEHYDE;4-(TERT-BUTOXYCARBONYLAMINO)BENZYLAMINE;(4-AMINOMETHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER;(4-AMINOMETHYL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER;4-(AMINOMETHYL)-1-N-BOC-ANILINE;TERT-BUTYL N-[4-(AMINOMETHYL)PHENYL]CARBAMATE;TERT-BUTYL 4-(AMINOMETHYL)PHENYL CARBAMATE;4-(Aminomethy)-1-N-Boc-aniline
• CAS NO: 220298-96-4
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28
• Mol File: 220298-96-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 64-68 °C(lit.)
• Boiling Point: 300.1 °C at 760 mmHg
• Flash Point: 135.3 °C
• Appearance: /
• Density: 1.12 g/cm³
• Vapor Pressure: 0.00114mmHg at 25°C
• Refractive Index: 1.564
• PKA: 13.68±0.70(Predicted)
• CAS DataBase Reference: tert-Butyl N-[4-(aminomethyl)phenyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl N-[4-(aminomethyl)phenyl]carbamate(220298-96-4)
• EPA Substance Registry System: tert-Butyl N-[4-(aminomethyl)phenyl]carbamate(220298-96-4)

Safety Data

• Hazard Codes: Xi,C,Xn
• Statements: 36/37/38-34-22-43
• Safety Statements: 26-36-45-36/37/39-22-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 220298-96-4(Hazardous Substances Data)

Usage

Uses

4-(Boc-amino)benzylamine is used in preparation of degradation agents for Cyclin dependent kinase useful for the treatment of cancer.

InChI:InChI=1/C12H18N2O2/c1-12(2,3)16-11(15)14-10-6-4-9(8-13)5-7-10/h4-7H,8,13H2,1-3H3,(H,14,15)

Upstream product

• 143090-18-0 tert-butyl N-(4-cyanophenyl)carbamate 
• 916578-53-5 tert-butyl (4-(chloromethyl)phenyl)carbamate 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 144072-29-7 tert-butyl N-[4-(hydroxymethyl)phenyl]carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 140401-57-6 4-(aminomethyl)aniline monohydrochloride 
• 4403-71-8 (4-aminomethyl)aniline 
• 630125-51-8 [4-(benzyloxycarbonylamino-methyl)phenyl]-carbamic acid tert-butyl ester 
• 285119-75-7 1,1-dimethylethyl [4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]carbamate 
• 1222185-06-9 (9H-fluoren-9-yl)methyl 4-aminobenzylcarbamate 
• 168050-39-3 [(4-Aminophenyl)methyl]carbamic acid,phenylmethyl ester 

Downstream Products

• 925920-84-9 C₁₄H₁₉ClN₂O₃ 
• 1039736-29-2 N-[4-(aminomethyl)phenyl]-N'-(4-chlorophenyl)urea 
• 1039736-28-1 N-[4-(aminomethyl)phenyl]-N'-(4-bromophenyl)urea 
• 926239-00-1 N-[4-(aminomethyl)phenyl]-N'-(4-fluorophenyl)urea 
• 1222185-07-0 methyl-4'-(4-(tert-butoxycarbonylamino)benzylcarbamoyl)-2,2'-bipyridine-4-carboxylate 
• 866005-62-1 (4-isothiocyanatomethyl-phenyl)-carbamic acid tert-butyl ester 
• 1346771-64-9 C₁₇H₂₃N₃O₄S 
• 1346771-63-8 C₁₈H₂₃N₃O₄S 
• 1346771-62-7 C₁₇H₂₂ClN₃O₄S 
• 1346771-61-6 C₁₇H₂₂BrN₃O₄S 
• 882430-31-1 {4-[(4-tert-butyl-benzyloxythiocarbonylamino)-methyl]-phenyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).

HISTONE LYSINE DEMETHYLASE INHIBITORS

The invention provides a compound which is an iV-oxalylglycine derivative of formula (I): a hydroxamic acid derivative of formula (II): or a heteroaryl derivative of fomula (III): wherein n; Z1; Z2; Y1; Y2; A; p; X1; X2; m; R4; B; R5; R6; R7; R8; R9; X3; R10; R11 and R12 are as defined herein, or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of the human 2-oxoglutarate-dependant JMJD2 subfamily of histone demethylases, in particular JMJD2E. Such inhibitors are useful in changing the epigenetic state of cells resulting in the inhibition / activation of chromatin remodelling, multiple gene activation / deactivation, and in treating cancer and other conditions characterised by undesirable cellular proliferation, and psychiatric disorders including depression.

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is -NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.